Prospective, Longitudinal, Observational Registry of Adult Patients with Hypophosphatasia (REG-HYPO)

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Oct 24, 2022

Keywords

ClinConnect Summary

This clinical trial, called REG-HYPO, is studying adults with a condition known as hypophosphatasia, which affects bone health and can cause problems like pain and fractures. The goal of the study is to follow these patients over time to understand their medical experiences better, especially as they see rheumatologists, doctors who specialize in joint and muscle issues.

To participate in this study, individuals need to be 18 years or older and have consistently low levels of a certain enzyme called alkaline phosphatase (below 40 IU/l) measured on at least three separate occasions. They should also have at least one symptom related to their joints or muscles. However, people with temporary forms of low alkaline phosphatase or those whose condition is caused by other diseases or medications are not eligible. Participants can expect regular check-ups and the opportunity to contribute valuable information that may help improve the understanding and treatment of hypophosphatasia in adults.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • men and women,
• • aged 18 and over, with no upper age limit, who have had a total alkaline phosphatase value of less than 40 IU/l on at least 3 occasions,
• • with at least one rheumatological symptom.
• Exclusion Criteria:
• • transient hypophosphatasia: absence of confirmation of a value below 40 IU/l on at least 3 samples,
• • secondary hypophosphatasia according to the expert rheumatologist (drugs, endocrine disease, other genetic disease...).